AMP Capital Investors Ltd trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 5.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,128 shares of the company’s stock after selling 4,841 shares during the quarter. AMP Capital Investors Ltd’s holdings in Allergan were worth $14,579,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of AGN. Edgewood Management LLC grew its holdings in Allergan by 24.3% during the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after acquiring an additional 869,248 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Allergan by 1,049.7% during the 4th quarter. Renaissance Technologies LLC now owns 726,269 shares of the company’s stock worth $118,803,000 after acquiring an additional 663,100 shares during the last quarter. Baupost Group LLC MA grew its holdings in Allergan by 21.9% during the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after acquiring an additional 531,600 shares during the last quarter. Asset Management One Co. Ltd. grew its holdings in Allergan by 4,852.6% during the 3rd quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock worth $103,108,000 after acquiring an additional 492,930 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Allergan during the 3rd quarter worth approximately $92,182,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.
Allergan plc (NYSE:AGN) opened at $158.41 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. Allergan plc has a 1 year low of $142.81 and a 1 year high of $256.80. The stock has a market cap of $54,790.00, a price-to-earnings ratio of -13.21, a P/E/G ratio of 1.11 and a beta of 1.29.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date is Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is presently -24.02%.
In other Allergan news, CFO Matthew M. Walsh acquired 2,000 shares of the stock in a transaction on Wednesday, February 21st. The shares were purchased at an average price of $160.94 per share, for a total transaction of $321,880.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Meury sold 58,879 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. Insiders have purchased a total of 7,200 shares of company stock worth $1,108,267 in the last quarter. 0.36% of the stock is owned by corporate insiders.
AGN has been the topic of a number of recent analyst reports. Argus downgraded shares of Allergan from a “buy” rating to a “hold” rating and dropped their price target for the stock from $256.80 to $160.07 in a research report on Thursday, December 7th. Deutsche Bank restated a “buy” rating and issued a $215.00 price target on shares of Allergan in a research report on Tuesday, January 9th. Barclays upgraded shares of Allergan from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $220.00 to $230.00 in a research report on Monday, January 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Vetr downgraded shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price target on the stock. in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $225.03.
TRADEMARK VIOLATION WARNING: “AMP Capital Investors Ltd Trims Holdings in Allergan plc (AGN)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3258696/amp-capital-investors-ltd-trims-holdings-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.